Clinical trials: sponsored by iOMEDICO AG
Lung Cancer
Tumour Registry Lung Cancer (TLK)
Overview of treatment reality in patients with bronchial carcinoma requiring systemic treatment and being treated by office-based oncologists in Germany.
- Trial name
- NCT01192919
- Volunteers
- 2,500 people
- Sponsor
- iOMEDICO AG
Non Hodgkin Lymphoma, Breast Cancer
Patient Preference for Pegfilgrastim (Neulasta®) Application Forms
The study aims to compare two application forms (pre-filled syringe and On-body injector) of the same active drug (pegfilgrastim) in adult patients under chemotherapy regarding patient preference and health economics.
- Trial name
- CONVENIENCE (NCT03619993)
- Testing
- On-body injector, Pre-filled syringe
- Where
- 48 sites in Germany
- Volunteers
- 404 people
- Sponsor
- iOMEDICO AG
Advanced Breast Cancer, HER2-positive Breast Cancer
A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer
This is a randomized, open-label, two-arm, phase III trial in Germany to investigate whether vinorelbine-based triple combination presents a less toxic treatment option than docetaxel-based triple combination in patients with…
- Trial name
- ATTILA (NCT03811418)
- Testing
- Trastuzumab, Pertuzumab, Vinorelbine
- Where
- Germany
- Sponsor
- iOMEDICO AG
Bone Metastasis
Bone Pain Score Validation Initiative
Translation and validation of the BOMET-QoL-10 questionnaire in Germany and assessment of its validity and responsiveness.
- Trial name
- ARIE (NCT02293642)
- Where
- Germany
- Volunteers
- 370 people
- Sponsor
- iOMEDICO AG
Metastatic Breast Cancer
Non-interventional Study With Nab-Paclitaxel (Abraxane®)
The purpose of this non-interventional study is to collect data on the efficacy and safety of Nab-Paclitaxel in the routine application.
- Trial name
- NABUCCO (NCT01689610)
- Where
- Germany
- Volunteers
- 705 people
- Sponsor
- iOMEDICO AG
Multiple Myeloma
Non -Interventional Study-Palliative Therapy of Multiple Myeloma With a Combination of Lenalidomide and Dexamethasone
Purpose of this non-interventional study is the documentation of efficacy and safety data of multiple myeloma therapy with a combined treatment of Lenalidomide and Dexamethasone in daily routine practice.
- Trial name
- REVLIMID-NIS (NCT00911105)
- Where
- 20 sites in Germany
- Volunteers
- 101 people
- Sponsor
- iOMEDICO AG
Metastatic Renal Cell Carcinoma, Failure of Exactly One Prior VEGF-targeted Therapy
Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2)
A single arm, open-label, multi-center phase IV clinical trial for patients with metastatic renal cell carcinoma, who have progressed on or after the first VEGF-targeted therapy.
- Trial name
- MARC-2 (NCT01266837)
- Testing
- Everolimus
- Where
- 8 sites in Germany
- Volunteers
- 64 people
- Sponsor
- iOMEDICO AG
Breast Cancer Recurrent, HER2/Neu-negative Carcinoma of Breast
Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab
This is a clinical trial with a crossover design to determine patients' preference for capecitabine in combination with bevacizumab or everolimus in combination with exemestane for advanced breast cancer patients and to evaluate…
- Conditions
- Breast Cancer Recurrent, HER2/Neu-negative Carcinoma of Breast, Hormone Receptor Positive Malignant Neoplasm of Breast
- Trial name
- IMPROVE (NCT02248571)
- Testing
- Bevacizumab, Capecitabine, Everolimus
- Where
- Germany
- Volunteers
- 85 people
- Sponsor
- iOMEDICO AG
Locally Advanced and/or Metastatic Renal Cell Carcinoma, Carcinoma, Renal Cell
First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma
Patients with advanced renal cell carcinoma (RCC) are classified according to Memorial Sloan-Kettering Cancer Center (MSKCC) criteria in three risk-groups: favourable, intermediate and poor.
- Conditions
- Locally Advanced and/or Metastatic Renal Cell Carcinoma, Carcinoma, Renal Cell, Clear-cell Metastatic Renal Cell Carcinoma
- Trial name
- FLIPPER (NCT01521715)
- Testing
- Pazopanib
- Where
- 8 sites in Germany
- Volunteers
- 44 people
- Sponsor
- iOMEDICO AG
Metastatic Breast Cancer
Capecitabine and Bevacizumab ± Vinorelbine in Metastatic Breast Cancer
The aim of the trial is to detect the superiority of the triple combination of capecitabine, bevacizumab and vinorelbine versus the combination of capecitabine and bevacizumab in patients with metastatic breast cancer.
- Trial name
- CARIN (NCT00868634)
- Testing
- capecitabine, bevacizumab, vinorelbine
- Where
- Germany
- Volunteers
- 600 people
- Sponsor
- iOMEDICO AG
Anemia
Clinical Tumor Anemia Registry (TAR)
The purpose of this registry is to record information of routine treatment of anemia in cancer patients in Germany. An overview of the current treatment of anemia in German outpatient centers and hospitals will be provided.
- Trial name
- TAR (NCT01795690)
- Where
- Germany
- Volunteers
- 1,018 people
- Sponsor
- iOMEDICO AG
MDS, AML
Non-interventional Study With Azacitidin (Vidaza®)
The purpose of this non-interventional study is to collect data on the efficiency and safety of Azacitidin in the routine application.
- Conditions
- MDS, AML, CMMOL
- Trial name
- Piaza (NCT01192945)
- Where
- Germany
- Volunteers
- 150 people
- Sponsor
- iOMEDICO AG
Antiemetic Therapy
Epidemiological EMESIS-Registry
The purpose of this registry is to record information on reality of anti-emetic therapies of cancer-patients in Germany. The outcome of this study is the efficacy of anti-emetic therapies dependent on the rate "complete and major…
- Trial name
- EMESIS (NCT00911222)
- Testing
- non-interventional
- Where
- Germany
- Volunteers
- 1,035 people
- Sponsor
- iOMEDICO AG